Male Cancer Market Research Report Forecast to 2020

Cancer, according to the WHO resulted in the death of around 8.2 million individuals worldwide in 2012. Around 14% of the world’s total annual deaths are as a result of various cancers. Modern medicine has extended the life expectancy of a cancer patient by a great margin. However newer cases are diagnosed every year globally, there is at present 14 million newly diagnosed individuals annually, according to the WHO. This is commonly as a result of the changing lifestyles, unhealthy diet, hereditary factors and exposure to carcinogenic elements. Nearly half of the general cancer cases that include: colorectal cancer, lymphoma, carcinoma, and lung cancer; are presented by men. This also includes breast cancer cases, where around 1% of the cases are exhibited by males worldwide. Male specific cancers include: prostate cancer, testicular cancer, and penile cancer.

Browse Premium Industry Research Report with Analysis: https://www.transparencymarketresearch.com/male-cancer-market.html

Among these, according to the WHO, the most common cause of death in men is prostate cancer. Male specific cancers are generally benign/malignant tumors that rarely undergo metastasis. A majority of disease complications are due to metastasis of cancers that result in complete peripheral organ damage. Prostate cancer was also found by the International Journal of Cancer, to be the major cause of death among autopsies of natural death cases in geriatric males. Genetic factors accounts as a doubled risk factor among above 45 age males. Diagnosis of prostate cancer is first undergone by physical examination; it is then confirmed by MRI or a tissue biopsy.

Treatment is surgery in case of primary stages. In case of advanced disease, radiation, chemotherapy and therapeutic drugs are prescribed to a patient. The survival rate for prostate cancer is at 99% in the US. Testicular cancer on the other hand has a far lesser prevalence, but unlike prostate cancer it is reported in a younger male population i.e. 20-39 years, according to the US journal: Seminars in Oncology. In the UK and U.S combined, nearly 10000 individuals are diagnosed annually with testicular cancer. However a majority of these cases are benign tumors and are therefore the most successfully cured form of cancer in humans with a high survival rate.

Request for Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3136

Surgery involving the castration of testis (inguinal orchiectomy) is usually necessary to prevent malignancy, it also forms as a safe mode of diagnostic confirmation as biopsies have been found to increase the proliferation of testicular cancer. The procedure itself is generally without any complications and cures a majority of cancer patients worldwide. However testicular cancer is highly specific to Caucasian populations and is extremely rare among Asian and African decent populations. Penile cancers are even rarer form of cancer, but unlike prostate and testicular cancer, they are commonly as a result of human papiloma virus (HPV) infection. Hence penile cancer rates are high in developing countries. Chemotherapy, antiviral therapy and surgical excision are the common mode of treatment for penile cancer.

That said, the market for male cancer therapeutics is highly fragmented hence not easily quantifiable, however the surgery and overall treatment market remains in billions of USD, with new diagnostic screening procedures and drug combinations being patented every year, each having their own market segment. They are at present one of the most sought after investment segment in the healthcare drugs industry. With entry of Asian players the prices too are bound to decrease, thereby potentially increasing the overall therapeutics market. In developing markets of Asia and South America, their poor standards along with their population size make for a large market, however unavailability of affordable diagnostic procedures and therapeutic drugs is thought to be the major reason why diagnosis is few in number and why the markets haven’t been proliferated as of yet. The rest of the world region is also bound to follow a similar pattern with increased awareness and diagnostic rates, the number of diagnosed individuals undergoing therapy in this region is however very small.

Pre Book this Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=3136<ype=S

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.